Company / Return on Assets (ROA)
Oruka Therapeutics, Inc. Return on Assets (ROA) History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-14.1%
FY2023
5-year range
-44.9% / -10.9%
FY2019-FY2023
Trend
+68.6%
vs FY2022
Sector context
#93 of 213
Health Care
What the data says
At -14.1%, Oruka Therapeutics, Inc.'s return on assets (roa) ranks #93 of 213 in the Health Care sector. Return on Assets (ROA) returned to growth in FY2023 after 2 years of decline, reaching -14.1%.
Based on SEC 10-K filings.
-14.1% in FY2023 with a 5-year CAGR of +256.8%.
Improved from -17.7% to -14.1% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -3.2pp
- 5-Year Change
- +256.8pp
- 10-Year Change
- -
Sector benchmark
#93 of 213 in Health CareTop 44% of 213This company -14.1% Sector average -24.2%
▼
+41.7% above sector average
Key checks
Key Insights
- In FY2023, return on assets (roa) increased 68.6% year-over-year.
- Currently 10.1pp above the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2020.
- Lowest return on assets (roa) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -14.1% | +68.6% |
| FY2022 | -44.9% | -153.0% |
| FY2021 | -17.7% | -63.1% |
| FY2020 | -10.9% | +88.3% |
| FY2019 | -92.9% | +65.7% |
| FY2018 | -270.9% | -103.7% |
| FY2017 | -133.0% | -186.2% |
| FY2016 | -46.5% | -89.8% |
| FY2015 | -24.5% | +43.1% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026